Datar secures FDA breakthrough nod for prostate cancer test

2019 04 22 18 53 8505 Lab Blood Liquid Samples 400

Oncology diagnostics developer Datar Cancer Genetics has secured breakthrough designation from the U.S. Food and Drug Administration (FDA) for its early-stage prostate cancer blood test.

TriNetra-Prostate identifies early-stage prostate cancer in men between the ages of 55 and 69 with more than 99% accuracy, the company said. It requires 5 ml of blood and is indicated for men with a serum prostate-specific antigen (PSA) measure of 3 ng/mL or higher, according to Datar.

Page 1 of 8
Next Page